Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2008

View Archived Issues

Alefacept found ineffective in treatment of severe alopecia areata

FDA approves Cleviprex for hypertension when oral therapy is not feasible

Novel radioligand for glycine transporter-1 under development by GSK in humans

Positive phase II results from studies of RAGE antagonist PF-04494700 in Alzheimer's disease

Phase II results encourage phase III investigation of LY-2062430 in Alzheimer's disease

Ustekinumab improves nail psoriasis in phase III trial

Recombinant adenovirus serotype 35 vectors evaluated in vivo as smallpox vaccine candidates

No significant improvement in psoriasis lesions seen with PTH (1-34) in phase IIa study

Evotec initiates phase I clinical trial of VR1 antagonist under development with Pfizer

4SC acquires 8 oncology projects from Nycomed

Astellas launches Mycamine in the U.K.

Kowa acquires ProEthic Pharmaceuticals

Emiliem and NIH Sign CRADA for development of novel mTOR inhibitors

Veridex acquires Immunicon corporation assets

Amicus successfully completes end of phase II meeting with FDA for Amigal

Novel agents for glaucoma reported in patent literature

Expression Genetics completes USD 12 million series B financing

Discovery of new anti-HIV agents reported in recent patents

Top-line results of phase II boceprevir study shows high SVR rate in HCV

AstraZeneca patents novel PDE4 inhibitors for asthma

Schering-Plough updates recent activities

Diovan HCT and Exforge approved for first-line blood pressure treatment

YM BioSciences reports positive results from phase II study of nimotuzumab in mCRC

CPEX and Serenity collaborate on drug candidate for urology indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...